Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GRAY NASDAQ:OHRP NASDAQ:ORGS NASDAQ:SPRB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRAYGraybug Vision$3.08-2.8%$2.68$5.00▼$22.12$8.64M1.22,165 shs33,051 shsOHRPOHR Pharmaceutical$7.37$1.60▼$6.28$1.08M0.84180,228 shsN/AORGSOrgenesis$0.17-78.1%$0.74$0.00▼$6.50$816K3.196,943 shs919 shsSPRBSpruce Biosciences$9.00+6,566.7%$7.59$0.06▼$9.70$76K2.43802,359 shs9,282 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRAYGraybug Vision0.00%+17.95%+7.33%+85.06%-35.98%OHRPOHR Pharmaceutical0.00%0.00%0.00%0.00%0.00%ORGSOrgenesis-78.08%-83.00%+672.73%-90.81%+16,999,900.00%SPRBSpruce Biosciences+10.43%+20.00%+10.09%+87.79%-74.07%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRAYGraybug Vision$3.08-2.8%$2.68$5.00▼$22.12$8.64M1.22,165 shs33,051 shsOHRPOHR Pharmaceutical$7.37$1.60▼$6.28$1.08M0.84180,228 shsN/AORGSOrgenesis$0.17-78.1%$0.74$0.00▼$6.50$816K3.196,943 shs919 shsSPRBSpruce Biosciences$9.00+6,566.7%$7.59$0.06▼$9.70$76K2.43802,359 shs9,282 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRAYGraybug Vision0.00%+17.95%+7.33%+85.06%-35.98%OHRPOHR Pharmaceutical0.00%0.00%0.00%0.00%0.00%ORGSOrgenesis-78.08%-83.00%+672.73%-90.81%+16,999,900.00%SPRBSpruce Biosciences+10.43%+20.00%+10.09%+87.79%-74.07%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGRAYGraybug Vision 0.00N/AN/AN/AOHRPOHR Pharmaceutical 0.00N/AN/AN/AORGSOrgenesis 0.00N/AN/AN/ASPRBSpruce Biosciences 2.00Hold$131.251,358.33% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGRAYGraybug VisionN/AN/AN/AN/A$1.67 per shareN/AOHRPOHR PharmaceuticalN/AN/AN/AN/A$3.86 per shareN/AORGSOrgenesis$662K1.23N/AN/A($6.58) per share-0.03SPRBSpruce Biosciences$4.91M1.03N/AN/A$1.88 per share4.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGRAYGraybug Vision-$35.60M-$24.23N/AN/AN/AN/A-77.61%-71.34%N/AOHRPOHR Pharmaceutical-$13.23MN/A0.00N/AN/AN/A-75.46%-71.18%N/AORGSOrgenesis-$55.36MN/A0.00∞N/A-3,827.81%N/A-130.18%11/11/2025 (Estimated)SPRBSpruce Biosciences-$47.92M-$86.21N/AN/AN/A-555.23%-62.10%-47.49%11/10/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGRAYGraybug VisionN/AN/AN/AN/AN/AOHRPOHR PharmaceuticalN/AN/AN/AN/AN/AORGSOrgenesisN/AN/AN/AN/AN/ASPRBSpruce BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGRAYGraybug VisionN/A10.7310.72OHRPOHR PharmaceuticalN/A3.733.73ORGSOrgenesisN/A0.070.07SPRBSpruce Biosciences0.015.365.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGRAYGraybug Vision49.94%OHRPOHR Pharmaceutical10.70%ORGSOrgenesis22.56%SPRBSpruce Biosciences91.71%Insider OwnershipCompanyInsider OwnershipGRAYGraybug Vision7.94%OHRPOHR Pharmaceutical12.50%ORGSOrgenesis5.66%SPRBSpruce Biosciences6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGRAYGraybug Vision271.57 million20.25 millionNot OptionableOHRPOHR Pharmaceutical32.83 millionN/ANot OptionableORGSOrgenesis1504.80 million4.53 millionNo DataSPRBSpruce Biosciences20562,00037.54 millionOptionableOHRP, GRAY, SPRB, and ORGS HeadlinesRecent News About These CompaniesOne new option listing and two option delistings on September 5thSeptember 5 at 12:21 PM | msn.comSpruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate UpdatesAugust 14, 2025 | businesswire.comSpruce Biosciences to enact 1-for-75 reverse stock splitJuly 24, 2025 | msn.comSpruce Biosciences Announces Reverse Stock SplitJuly 24, 2025 | finance.yahoo.comHMNC Brain Health and Spruce Biosciences Announce First Patient Dosed in Phase 2 TAMARIND Trial For Major Depressive DisorderJuly 22, 2025 | globenewswire.comSPRB Spruce Biosciences, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comSpruce Biosciences gets conditional approval to resume trading on Nasdaq Capital MarketJune 13, 2025 | msn.comSpruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital MarketJune 12, 2025 | finance.yahoo.comSpruce Biosciences’ Compliance Plan Accepted by NasdaqJune 12, 2025 | tipranks.comSpruce Biosciences’ SWOT analysis: stock pivots amid clinical setbacksMay 7, 2025 | investing.comSpruce Biosciences Inc Ordinary SharesMay 6, 2025 | morningstar.comMSpruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesMay 6, 2025 | finance.yahoo.comSpruce Axes 55% of Staff, Leaving Shoestring Crew To Focus on New Rare Disease AssetApril 28, 2025 | biospace.comBSpruce halves head count, narrowing focus to get ex-BioMarin drug to FDAApril 28, 2025 | fiercebiotech.comFSpruce Biosciences (SPRB) Receives a Hold from RBC CapitalApril 17, 2025 | markets.businessinsider.comSpruce Biosciences, Inc. (NASDAQ:SPRB) Q1 2023 Earnings Call TranscriptApril 17, 2025 | insidermonkey.comSpruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)April 15, 2025 | standard-journal.comSWith BioMarin deal, Spruce Biosciences hits reset on rare-disease drugApril 15, 2025 | bizjournals.comSpruce Biosciences, Inc. (SPRB) Corporate Update Conference Call (Transcript)April 15, 2025 | seekingalpha.comSpruce Biosciences reports delayed annual filingApril 3, 2025 | investing.comNew MarketBeat Followers Over TimeOHRP, GRAY, SPRB, and ORGS Company DescriptionsGraybug Vision NASDAQ:GRAY$3.08 -0.09 (-2.84%) As of 09/5/2025Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.OHR Pharmaceutical NASDAQ:OHRPOHR Pharmaceutical, Inc. operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc. that focuses on advancing NeuBase's peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. OHR Pharmaceutical, Inc. is headquartered in New York, New York.Orgenesis NASDAQ:ORGS$0.17 -0.61 (-78.08%) As of 09/5/2025 01:58 PM EasternOrgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.Spruce Biosciences NASDAQ:SPRB$9.00 +8.87 (+6,566.67%) As of 09/5/2025 03:57 PM EasternSpruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
